The Leukaemia Research Group (LRG)

The Leukaemia Research Group is headed by Professor Øystein Bruserud.

The research has a major focus on the hematological malignancy acute myeloid leukaemia (AML); an aggressive disease that can be cured only by intensive chemotherapy eventually in combination with stem cell transplantation. Our main research areas are:

  • Preleukaemic disorders
  • Biological and functional characterization of primary human AML cells and their interactions with stromal elements
  • Experimental studies of efficiency and toxicity (especially immunotoxicity) of both new targeted therapies and already established therapeutic strategies in human AML.




Øystein Bruserud receives research prize from Helse Vest for his achievments in the field of AML research

Through his work, Bruserud has contributed considerably in the field of hematological research. His commitment has created the foundation for research activity on AML, on a high national and international level, in the Helse Vest region.


Key collaborators at Haukeland University Hospital, Department of Medicine, Section for Hematology:

Consultant and Head of Department Aymen Bushra Ahmed

Consultant Håkon Reikvam

Consultant Astrid Olsnes

Collaborator, Bergen University College:

Assistant Professor Elisabeth Ersvær

Assistant Professor Anita Ryningen

Key collaborators, Department of Biomedicine, University of Bergen:

Professor Frode Berven

Professor Stein Ove Døskeland

Professor Frode Selheim

External collaborators:

Professor Guro Lind, The Norwegian Cancer Hospital, University of Oslo,  Oslo, Norway.

Professor Tobias Gedde-Dahl, The National Hospital, University of Oslo, Oslo, Norway.

Professor Stefan Rose-John, University of Kiel, Germany.

Professor Antonio Lavecchia, University of Napoli, Italy.

Scientist Frederic Pendino, Institut COCHIN Inserm U1016 - CNRS 8104 - Université Paris Descartes, Paris, France.

Advanced equipment:

  • Beta-counter for 96-well microtiter format.
  • BD Verse Flow cytometer.